Current Problems in Surgery
Volume 45, Issue 3 , Pages 156-250 , March 2008

Recent Advances in Thyroid Cancer

  • Elizabeth G. Grubbs, MD

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Thereasa A. Rich, MS

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Guojun Li, MD, PhD

      Affiliations

    • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Erich M. Sturgis, MD, MPH

      Affiliations

    • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Maher N. Younes, MD

      Affiliations

    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Jeffrey N. Myers, MD, PhD

      Affiliations

    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Beth Edeiken-Monroe, MD

      Affiliations

    • Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Bruno D. Fornage, MD

      Affiliations

    • Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Douglas P. Monroe, MD

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Gregg A. Staerkel, MD

      Affiliations

    • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Michelle D. Williams, MD

      Affiliations

    • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Steven G. Waguespack, MD

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Mimi I. Hu, MD

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Gilbert Cote, PhD

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Robert F. Gagel, MD

      Affiliations

    • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
    • Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • James Cohen, MD, PhD

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, Oregon Health Sciences University, OR
    • ,
  • Randal S. Weber, MD

      Affiliations

    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Daniel A. Anaya, MD

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • F. Chris Holsinger, MD

      Affiliations

    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Nancy D. Perrier, MD

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Gary L. Clayman, DMD, MD

      Affiliations

    • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    • ,
  • Douglas B. Evans, MD

      Affiliations

    • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106–130
  2. Surveillance Epidemiology and End Results (SEER) Program, 2006. www.seer.cancer.govAccessed October 2006
  3. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88(5):1139–1148
  4. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101(1):3–27
  5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–2167
  6. Mangano JJ. A post-Chernobyl rise in thyroid cancer in Connecticut, USA. Eur J Cancer Prev. 1996;5(1):75–81
  7. Haselkorn T, Bernstein L, Preston-Martin S, et al. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11(2):163–170
  8. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16(1):47–53
  9. Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150(2):133–139
  10. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol. 2005;26(2):87–90
  11. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid (A “normal” finding in Finland). A systematic autopsy study Cancer. 1985;56(3):531–538
  12. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108
  13. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–2150
  14. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83(1):18–29
  15. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166
  16. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–156
  17. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97(1):72–81
  18. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol. 1999;16(1):64–69
  19. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. http://www-dep.iarc.fr/globocan/globocan.htmAccessed October 2006
  20. Colonna M, Grande E, Jonasson JG Eurocare Working G.. Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study). Eur J Cancer. 2006;42(15):2598–2608
  21. Little JB. Radiation carcinogenesis. Carcinogenesis. 2000;21(3):397–404
  22. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259–277
  23. Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid. 2002;12(10):889–896
  24. Sources and effects of ionizing radiation (United Nations Scientific Committee on the Effects of Atomic Radiation). New York: United Nations Publication; 2000;
  25. Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Pediatr Radiol. 2002;32(4):232–237discussion 242-4
  26. Sarne D, Schneider AB. External radiation and thyroid neoplasia. Endocrinol Metab Clin North Am. 1996;25(1):181–195
  27. Holm LE, Dahlqvist I, Israelsson A, Lundell G. Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med. 1980;303(4):188–191
  28. Holm LE, Wiklund KE, Lundell GE, et al. Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Natl Cancer Inst. 1988;80(14):1132–1138
  29. Ron E. Cancer risks from medical radiation. Health Phys. 2003;85(1):47–59
  30. Kerber RA, Till JE, Simon SL, et al. A cohort study of thyroid disease in relation to fallout from nuclear weapons testing. JAMA. 1993;270(17):2076–2082
  31. Prentice RL, Kato H, Yoshimoto K, Mason M. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Natl Cancer Inst Monogr. 1982;62:207–212
  32. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306
  33. Moysich KB, Menezes RJ, Michalek AM. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol. 2002;3(5):269–279
  34. Kopecky KJ, Stepanenko V, Rivkind N, et al. Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. Radiat Res. 2006;166(2):367–374
  35. Tronko MD, Howe GR, Bogdanova TI, et al. A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst. 2006;98(13):897–903
  36. Cardis E, Kesminiene A, Ivanov V, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005;97(10):724–732
  37. Ivanov VK, Gorski AI, Tsyb AF, et al. Radiation-epidemiological studies of thyroid cancer incidence among children and adolescents in the Bryansk oblast of Russia after the Chernobyl accident (1991-2001 follow-up period). Radiat Environ Biophys. 2006;45(1):9–16
  38. Negri E, Ron E, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control. 1999;10(2):131–142
  39. Kolonel LN, Hankin JH, Wilkens LR, et al. An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control. 1990;1(3):223–234
  40. Franceschi S, Boyle P, Maisonneuve P, et al. The epidemiology of thyroid carcinoma. Crit Rev Oncog. 1993;4(1):25–52
  41. Ron E, Kleinerman RA, Boice JD, et al. A population-based case-control study of thyroid cancer. J Natl Cancer Inst. 1987;79(1):1–12
  42. Franceschi S, Fassina A, Talamini R, et al. Risk factors for thyroid cancer in northern Italy. Int J Epidemiol. 1989;18(3):578–584
  43. Franceschi S, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control. 1999;10(6):583–595
  44. Levi F, Franceschi S, La Vecchia C, et al. Previous thyroid disease and risk of thyroid cancer in Switzerland. Eur J Cancer. 1991;27(1):85–88
  45. Mack WJ, Preston-Martin S, Bernstein L, et al. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev. 1999;8(11):991–997
  46. McTiernan AM, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst. 1984;73(3):575–581
  47. Preston-Martin S, Jin F, Duda MJ, Mack WJ. A case-control study of thyroid cancer in women under age 55 in Shanghai (People’s Republic of China). Cancer Causes Control. 1993;4(5):431–440
  48. Norton JA, Doppman JD, Jensen RT. Cancer of the endocrine system. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. 3rd edition. Philadelphia: Lippincott; 1989;p. 1314–1344
  49. Horn-Ross PL, Morris JS, Lee M, et al. Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001;10(9):979–985
  50. Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid. 2005;15(2):152–157
  51. Bosetti C, Negri E, Kolonel L, et al. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (international). Cancer Causes Control. 2002;13(8):765–775
  52. Markaki I, Linos D, Linos A. The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer. 2003;39(13):1912–1919
  53. Divi RL, Doerge DR. Inhibition of thyroid peroxidase by dietary flavonoids. Chem Res Toxicol. 1996;9(1):16–23
  54. Horn-Ross PL, Hoggatt KJ, Lee MM. Phytoestrogens and thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev. 2002;11(1):43–49
  55. Haselkorn T, Stewart SL, Horn-Ross PL. Why are thyroid cancer rates so high in Southeast Asian women living in the United States? (The Bay area thyroid cancer study). Cancer Epidemiol Biomarkers Prev. 2003;12(2):144–150
  56. Mack WJ, Preston-Martin S, Bernstein L, Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol. 2002;12(6):395–401
  57. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23(21):4742–4754
  58. Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control. 1999;10(2):143–155
  59. La Vecchia C, Ron E, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control. 1999;10(2):157–166
  60. Navarro Silvera SA, Miller AB, Rohan TE. Risk factors for thyroid cancer: a prospective cohort study. Int J Cancer. 2005;116(3):433–438
  61. Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer. 2001;93(5):745–750
  62. Akslen LA, Nilssen S, Kvale G. Reproductive factors and risk of thyroid cancer (A prospective study of 63,090 women from Norway). Br J Cancer. 1992;65(5):772–774
  63. Correa P, Chen VW. Endocrine gland cancer. Cancer. 1995;75(1 suppl):338–352
  64. Ericsson UB, Lindgarde F. Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis. J Intern Med. 1991;229(1):67–71
  65. Knudsen N, Bulow I, Laurberg P, et al. Alcohol consumption is associated with reduced prevalence of goitre and solitary thyroid nodules. Clin Endocrinol (Oxf). 2001;55(1):41–46
  66. Mack WJ, Preston-Martin S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control. 2003;14(8):773–785
  67. Galanti MR, Hansson L, Lund E, et al. Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 1996;5(6):425–431
  68. Rossing MA, Cushing KL, Voigt LF, et al. Risk of papillary thyroid cancer in women in relation to smoking and alcohol consumption. Epidemiology. 2000;11(1):49–54
  69. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001;86(11):5307–5312
  70. Hemminki K, Li X, Plna K, et al. The nation-wide Swedish family-cancer database-updated structure and familial rates. Acta Oncol. 2001;40(6):772–777
  71. Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005;90(10):5747–5753
  72. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004;23(38):6445–6470
  73. Lindor NM, Greene MH. The concise handbook of family cancer syndromes (Mayo Familial Cancer Program). J Natl Cancer Inst. 1998;90(14):1039–1071
  74. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma (Molecular features, pathophysiology and clinical implications). Virchows Arch. 1997;431(1):1–9
  75. Fernandez RM, Pecina A, Antinolo G, et al. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma. Thyroid. 2006;16(4):411–417
  76. Alsanea O, Clark OH. Familial thyroid cancer. Curr Opin Oncol. 2001;13(1):44–51
  77. Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22(3):183–198
  78. Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? (Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome). J Med Genet. 2004;41(5):323–326
  79. Ishikawa Y, Sugano H, Matsumoto T, et al. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer. 1999;85(6):1345–1352
  80. Eng C. Familial papillary thyroid cancer—many syndromes, too many genes?. J Clin Endocrinol Metab. 2000;85(5):1755–1757
  81. McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69(2):440–446
  82. Takezaki T, Hirose K, Inoue M, et al. Risk factors of thyroid cancer among women in Tokai, Japan. J Epidemiol. 1996;6(3):140–147
  83. Zheng R, Dahlstrom KR, Wei Q, Sturgis EM. Gamma radiation-induced apoptosis, G2 delay, and the risk of salivary and thyroid carcinomas—a preliminary report. Head Neck. 2004;26(7):612–618
  84. Xiong P, Zheng R, Wang LE, et al. A pilot case-control study of gamma-radiation sensitivity and risk of papillary thyroid cancer. Thyroid. 2005;15(2):94–99
  85. Sigurdson AJ, Hauptmann M, Alexander BH, et al. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutat Res. 2005;586(2):173–188
  86. Ho T, Zhao C, Zheng R, et al. Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch Otolaryngol Head Neck Surg. 2006;132(7):756–761
  87. Hernandez A, Cespedes W, Xamena N, et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett. 2003;190(1):37–44
  88. Sturgis EM, Zhao C, Zheng R, Wei Q. Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope. 2005;115(6):938–945
  89. Silva SN, Gil OM, Oliveira VC, et al. Association of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2407–2412
  90. Rogounovitch TI, Saenko VA, Ashizawa K, et al. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep. 2006;15(4):949–956
  91. Ho T, Li G, Zhao C, et al. RET polymorphisms and haplotypes and risk of differentiated thyroid cancer. Laryngoscope. 2005;115(6):1035–1041
  92. Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501–511
  93. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 2004;183(2):249–256
  94. Carniti C, Perego C, Mondellini P, et al. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res. 2003;63(9):2234–2243
  95. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57(21):4710–4713
  96. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev. 1994;15(2):202–232
  97. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989;4(2):159–164
  98. Manenti G, Pilotti S, Re FC, et al. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer. 1994;30A(7):987–993
  99. Suchy B, Waldmann V, Klugbauer S, Rabes HM. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer. 1998;77(6):952–955
  100. McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):221–234
  101. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–2326
  102. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. [corrected] Science. 2000;289(5483):1357–1360
  103. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26(8):1016–1023
  104. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract. 2003;9(2):128–136
  105. Sobrinho-Simoes M, Preto A, Rocha AS, et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 2005;447(5):787–793
  106. Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001;22(5):631–656
  107. Krohn K, Fuhrer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005;26(4):504–524
  108. Matsuo K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab. 1993;76(6):1446–1451
  109. Spambalg D, Sharifi N, Elisei R, et al. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab. 1996;81(11):3898–3901
  110. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454–1457
  111. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–262
  112. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94–101
  113. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238–4245
  114. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24(44):6646–6656
  115. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–6379
  116. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446(6):589–595
  117. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399–5404
  118. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3(5):383–394
  119. Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23(36):6056–6063
  120. Kodama Y, Asai N, Kawai K, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96(3):143–148
  121. Carlomagno F, Vitagliano D, Guida T, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 2002;62(4):1077–1082
  122. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–563
  123. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55(23):5617–5620
  124. Viglietto G, Chiappetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995;11(6):1207–1210
  125. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–160
  126. Miller FD, Kaplan DR. On Trk for retrograde signaling. Neuron. 2001;32(5):767–770
  127. Wajjwalku W, Nakamura S, Hasegawa Y, et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res. 1992;83(7):671–675
  128. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005;16(2):179–186
  129. Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295–4301
  130. St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146(3):1145–1153
  131. Morikawa Y, Ishihara Y, Tohya K, et al. Expression of the fibroblast growth factor receptor-1 in human normal tissues and tumors determined by a new monoclonal antibody. Arch Pathol Lab Med. 1996;120(5):490–496
  132. Onose H, Emoto N, Sugihara H, et al. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol. 1999;140(2):169–173
  133. Trovato M, Villari D, Bartolone L, et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid. 1998;8(2):125–131
  134. Belfiore A, Gangemi P, Costantino A, et al. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 1997;82(7):2322–2328
  135. Ruco LP, Stoppacciaro A, Ballarini F, et al. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol. 2001;194(1):4–8
  136. Scarpino S, D’Alena FC, Di Napoli A, et al. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol. 2003;199(2):243–250
  137. Younes MN, Yazici YD, Kim S, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res. 2006;12(11 Pt 1):3425–3434
  138. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004;10(24):8594–8602
  139. Takeyama H, Shioya H, Mori Y, et al. Usefulness of radio-guided surgery using technetium-99m methoxyisobutylisonitrile for primary and secondary hyperparathyroidism. World J Surg. 2004;28(6):576–582
  140. Asmis LM, Gerber H, Kaempf J, Studer H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol. 1995;145(3):513–520
  141. Holting T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol. 1995;132(2):229–235
  142. Chen H, Nicol TL, Udelsman R. Clinically significant, isolated metastatic disease to the thyroid gland. World J Surg. 1999;23(2):177–180discussion 181
  143. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6):1967–1976
  144. Lyshchik A, Higashi T, Asato R, et al. Thyroid gland tumor diagnosis at US elastography. Radiology. 2005;237(1):202–211
  145. Yasuoka H, Nakamura Y, Zuo H, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2005;18(8):1127–1133
  146. Katoh R, Miyagi E, Kawaoi A, et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol. 1999;30(8):891–897
  147. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001;11(9):877–881
  148. Volante M, Croce S, Pecchioni C, Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol. 2002;15(10):1038–1043
  149. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87(4):1810–1813
  150. Noguchi S, Yamashita H, Murakami N, et al. Small carcinomas of the thyroid (A long-term follow-up of 867 patients). Arch Surg. 1996;131(2):187–191
  151. Erickson LA, Yousef OM, Jin L, et al. p27kip1 expression distinguishes papillary hyperplasia in Graves’ disease from papillary thyroid carcinoma. Mod Pathol. 2000;13(9):1014–1019
  152. Tung WS, Shevlin DW, Bartsch D, et al. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog. 1996;15(1):5–10
  153. Khoo ML, Beasley NJ, Ezzat S, et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87(4):1814–1818
  154. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992;52(5):1369–1371
  155. Frates MC, Benson CB, Doubilet PM, et al. Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules?. J Ultrasound Med. 2003;22(2):127–131quiz 132-4
  156. Monchik JM, De Petris G, De Crea C. Occult papillary carcinoma of the thyroid presenting as a cervical cyst. Surgery. 2001;129(4):429–432
  157. Pardal-de-Oliveira F, Vieira F. Occult papillary carcinoma of the thyroid gland with extensive osseous metastases—a case report with review of the literature. Pathol Res Pract. 1999;195(10):711–714discussion 715-6
  158. Attie JN, Khafif RA, Steckler RM. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg. 1971;122(4):464–471
  159. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87(5):1941–1946
  160. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas (Prevalence by palpation and ultrasonography). Arch Intern Med. 1994;154(16):1838–1840
  161. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178(3):687–691
  162. Kang HW, No JH, Chung JH, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid. 2004;14(1):29–33
  163. Liebeskind A, Sikora AG, Komisar A, et al. Rates of malignancy in incidentally discovered thyroid nodules evaluated with sonography and fine-needle aspiration. J Ultrasound Med. 2005;24(5):629–634
  164. Brander A, Viikinkoski P, Tuuhea J, et al. Clinical versus ultrasound examination of the thyroid gland in common clinical practice. J Clin Ultrasound. 1992;20(1):37–42
  165. Jarlov AE, Hegedus L, Gjorup T, Hansen JE. Accuracy of the clinical assessment of thyroid size. Dan Med Bull. 1991;38(1):87–89
  166. Koike E, Noguchi S, Yamashita H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg. 2001;136(3):334–337
  167. Watters DA, Ahuja AT, Evans RM, et al. Role of ultrasound in the management of thyroid nodules. Am J Surg. 1992;164(6):654–657
  168. Kerr L. High-resolution thyroid ultrasound: the value of color Doppler. Ultrasound Q. 1994;12(1):21–44
  169. Brkljacic B, Cuk V, Tomic-Brzac H, et al. Ultrasonic evaluation of benign and malignant nodules in echographically multinodular thyroids. J Clin Ultrasound. 1994;22(2):71–76
  170. Kakkos SK, Scopa CD, Chalmoukis AK, et al. Relative risk of cancer in sonographically detected thyroid nodules with calcifications. J Clin Ultrasound. 2000;28(7):347–352
  171. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946–954discussion 954-5
  172. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489–494discussion 494-6
  173. Martin HE. Biopsy by needle puncture and aspiration. EB Am Surg. 1930;92:169–181
  174. Stewart F. The diagnosis of tumors by aspiration. Am J Pathol. 1933;9:801–812
  175. Frazell ELFF. Papillary carcinoma of the thyroid: a review of 25 years of experience. Cancer. 1958;11:895–922
  176. Crockford PM, Bain GO. Fine-needle aspiration biopsy of the thyroid. Can Med Assoc J. 1974;110(9):1029–1032
  177. Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules (Use of fine-needle aspiration and needle biopsy). JAMA. 1979;241(5):481–484
  178. Yang GC, Liebeskind D, Messina AV. Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: data from 1135 biopsies with a two- to six-year follow-up. Thyroid. 2001;11(6):581–589
  179. Kim SJ, Kim EK, Park CS, et al. Ultrasound-guided fine-needle aspiration biopsy in nonpalpable thyroid nodules: is it useful in infracentimetric nodules?. Yonsei Med J. 2003;44(4):635–640
  180. Baloch ZW, Tam D, Langer J, et al. Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol. 2000;23(6):425–429
  181. Yokozawa T, Miyauchi A, Kuma K, Sugawara M. Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy. Thyroid. 1995;5(2):141–145
  182. Binyousef HM, Alzahrani AS, Al-Sobhi SS, et al. Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer. World J Surg. 2004;28(11):1110–1114
  183. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery. 2001;130(6):971–977
  184. Lewis BD, Hay ID, Charboneau JW, et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002;178(3):699–704
  185. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines (Laboratory support for the diagnosis and monitoring of thyroid disease). Thyroid. 2003;13(1):3–126
  186. Clark DPFW. Thyroid Cytopathology. New York: Springer; 2005;
  187. DeMay R. Thyroid (The Art and Science of Cytopathology). In: Chicago: ASCP Press; 1996;p. 704–713
  188. Kini S. Adequacy, reporting system, and cytopreparatory technique. New York: Igaku-Shoin; 1987;
  189. Hamburger JI, Husain M. Semiquantitative criteria for fine-needle biopsy diagnosis: reduced false-negative diagnoses. Diagn Cytopathol. 1988;4(1):14–17
  190. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987;31(5):587–590
  191. Nguyen GK, Ginsberg J, Crockford PM. Fine-needle aspiration biopsy cytology of the thyroid (Its value and limitations in the diagnosis and management of solitary thyroid nodules). Pathol Annu. 1991;26(Pt 1):63–91
  192. Guidelines of the Papanicolaou Society of Cytopathology for the Examination of Fine-Needle Aspiration Specimens from Thyroid Nodules (The Papanicolaou Society of Cytopathology Task Force on Standards of Practice). Mod Pathol. 1996;9(6):710–715
  193. Rosai J. Standardized reporting of surgical pathology diagnoses for the major tumor types. A proposal. The Department of Pathology, Memorial Sloan-Kettering Cancer Center. Am J Clin Pathol. 1993;100(3):240–255
  194. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. AJCC Cancer Staging Manual. 6th ed.. New York: Springer-Verlag; 2002;
  195. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma (A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group). Eur J Cancer. 1979;15(8):1033–1041
  196. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088–1095
  197. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–953
  198. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050–1057discussion 1057-8
  199. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428
  200. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery. 1995;118(6):1131–1136discussion 1136-8
  201. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome (National Thyroid Cancer Treatment Cooperative Study Registry Group). Cancer. 1998;83(5):1012–1021
  202. Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer. 1996;78(3):493–501
  203. Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88(8):1902–1908
  204. DeLellis RA, Williams D. Pathology and Genetics of Tumors of the Endocrine Organs. Lyon: IARCPress; 2004;
  205. Heffess CS, Thompson LD. Minimally invasive follicular thyroid carcinoma. Endocr Pathol. 2001;12(4):417–422
  206. Thompson LD, Wieneke JA, Paal E, et al. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 2001;91(3):505–524
  207. LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol. 2004;11(6):279–287
  208. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. [see comments] Cancer. 1998;83(12):2638–2648
  209. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–424
  210. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66
  211. Kouvaraki MA, Lee JE, Shapiro SE, et al. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery. 2004;136(6):1183–1191
  212. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–260
  213. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70(3):511–518
  214. Esnaola NF, Cantor SB, Sherman SI, et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001;130(6):921–930
  215. Cody HS, Shah JP. Locally invasive, well-differentiated thyroid cancer (22 years’ experience at Memorial Sloan-Kettering Cancer Center). Am J Surg. 1981;142(4):480–483
  216. Mizuno S, Funahashi H, Sugiura H, et al. Study on extensive lymph node dissection: metastatic lymph nodes in papillary carcinoma of the thyroid. Nippon Geka Gakkai Zasshi. 1986;87(8):883–888
  217. Tisell LE, Nilsson B, Molne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20(7):854–859
  218. Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab. 1983;56(6):1131–1138
  219. Rossi RL, Cady B, Silverman ML, et al. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg. 1986;10(4):612–622
  220. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–142
  221. Grodski S, Cornford L, Sywak M, et al. Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique. ANZ J Surg. 2007;77(4):203–208
  222. Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002;128(7):751–758
  223. Kouvaraki MA, Shapiro SE, Lee JE, et al. Surgical management of thyroid carcinoma. J Natl Compr Canc Netw. 2005;3(3):458–466
  224. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–28
  225. Qubain SW, Nakano S, Baba M, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131(3):249–256
  226. Machens A, Schneyer U, Holzhausen HJ, et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery. 2004;136(5):1083–1087
  227. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local recurrence occurs with “berry picking” than neck dissection in thyroid cancer. Am Surg. 2003;69(3):191–196discussion 196-7
  228. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151(2):308–319
  229. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today. 1994;24(2):112–121
  230. Hedayati N, McHenry CR. The clinical significance of an isofunctioning thyroid nodule. Am Surg. 2003;69(4):311–315discussion 315-6
  231. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245(4):604–610
  232. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970;26(5):1053–1060
  233. Noguchi S, Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am. 1987;67(2):251–261
  234. Noguchi S, Murakami N, Yamashita H, et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg. 1998;133(3):276–280
  235. Thyroid Carcinoma. In: Clinical Practice Guidelines in Oncology (Version 2.2007). Vol. 2007:National Comprehensive Cancer Network, Inc; 2007;http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdfAccessed July 2007
  236. Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 1992;72(3):667–697
  237. Arturi F, Scarpelli D, Coco A, et al. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid. 2003;13(4):341–343
  238. Cetani F, Tonacchera M, Pinchera A, et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. J Endocrinol Invest. 1999;22(4):273–278
  239. Sheils OM, Sweeney EC. TSH receptor status of thyroid neoplasms—TaqMan RT-PCR analysis of archival material. J Pathol. 1999;188(1):87–92
  240. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81(12):4318–4323
  241. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34(7-8):554–564
  242. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–1242
  243. Landau D, Vini L, A’Hern R, Harmer C. Thyroid cancer in children: the Royal Marsden Hospital experience. Eur J Cancer. 2000;36(2):214–220
  244. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84(11):3877–3885
  245. Belfiore A, Russo D, Vigneri R, Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf). 2001;55(6):711–718
  246. Matsuzu K, Segade F, Matsuzu U, et al. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid. 2004;14(10):806–812
  247. Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91(7):2592–2599
  248. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;75(2):344–350
  249. Bogazzi F, Bartalena L, Gasperi M, et al. The various effects of amiodarone on thyroid function. Thyroid. 2001;11(5):511–519
  250. Chen H, Nicol TL, Zeiger MA, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy?. Ann Surg. 1998;227(4):542–546
  251. Testini M, Rosato L, Avenia N, et al. The impact of single parathyroid gland autotransplantation during thyroid surgery on postoperative hypoparathyroidism: a multicenter study. Transplant Proc. 2007;39(1):225–230
  252. Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007;92(1):3–9
  253. Eustatia-Rutten CF, Corssmit EP, Pereira AM, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf). 2006;64(3):284–291
  254. Sun L, Davies TF, Blair HC, et al. TSH and bone loss. Ann N Y Acad Sci. 2006;1068:309–318
  255. Karner I, Hrgovic Z, Sijanovic S, et al. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res. 2005;10(11):480–488
  256. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81(12):4278–4289
  257. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–1252
  258. Parle JV, Maisonneuve P, Sheppard MC, et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358(9285):861–865
  259. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238
  260. DeGroot LJ, Jameson JL. Endocrinology. 5th ed.. Philadelphia: Elsevier Saunders; 2006;
  261. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531–544
  262. Ponder BA, Ponder MA, Coffey R, et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet. 1988;1(8582):397–401
  263. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367(6461):375–376
  264. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994;331(13):828–835
  265. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–5671
  266. Yen TW, Shapiro SE, Gagel RF, et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134(6):890–899discussion 899-901
  267. Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 2001;17(10):580–589
  268. Schuchardt A, D’Agati V, Larsson-Blomberg L, et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367(6461):380–383
  269. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003;8(6):531–538
  270. Pasini B, Hofstra RM, Yin L, et al. The physical map of the human RET proto-oncogene. Oncogene. 1995;11(9):1737–1743
  271. De Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27(5):535–560
  272. Anders J, Kjar S, Ibanez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem. 2001;276(38):35808–35817
  273. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 1995;11(10):2039–2045
  274. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature. 1996;384(6608):467–470
  275. Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron. 1998;21(6):1291–1302
  276. Milbrandt J, de Sauvage FJ, Fahrner TJ, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron. 1998;20(2):245–253
  277. Kjaer S, Ibanez CF. Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem. 2003;278(48):47898–47904
  278. de Groot JW, Plaza Menacho I, Schepers H, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery. 2006;139(6):806–814
  279. Nunziata V, Giannattasio R, Di Giovanni G, et al. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple’s syndrome). Clin Endocrinol (Oxf). 1989;30(1):57–63
  280. Bugalho MJ, Domingues R, Santos JR, et al. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007;141(1):90–95
  281. Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989;111(10):802–806
  282. Verdy M, Weber AM, Roy CC, et al. Hirschsprung’s disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr. 1982;1(4):603–607
  283. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4-5):441–467
  284. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994;3(2):237–241
  285. Gujral TS, Singh VK, Jia Z, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 2006;66(22):10741–10749
  286. Songyang Z, Carraway KL, Eck MJ, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995;373(6514):536–539
  287. Cranston AN, Carniti C, Oakhill K, et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res. 2006;66(20):10179–10187
  288. Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer (Phase II study). J Cancer Res Clin Oncol. 1990;116(1):21–23
  289. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine (The Groupe d’Etude des Tumeurs a Calcitonine (GETC)). Br J Cancer. 1995;71(2):363–365
  290. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310
  291. Grohn P, Kumpulainen E, Jakobsson M. Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol. 1990;29(7):950–951
  292. Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000;41(1):93–103
  293. Schott M, Feldkamp J, Klucken M, et al. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother. 2002;51(11-12):663–668
  294. Mahler C, Verhelst J, de Longueville M, Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf). 1990;33(2):261–269
  295. Smid WM, Dullaart RP. Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth J Med. 1992;40(5-6):240–243
  296. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85(3):983–988
  297. Busse D, Yakes FM, Lenferink AE, Arteaga CL. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin Oncol. 2001;28(5 suppl 16):47–55
  298. Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery. 2002;132(6):960–966discussion 966-7
  299. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13(2):535–540
  300. de Groot JW, Zonnenberg BA, Quarles van Ufford-Mannesse P, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–3469
  301. Lanzi C, Cassinelli G, Pensa T, et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer. 2000;85(3):384–390
  302. Lanzi C, Cassinelli G, Cuccuru G, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003;60(7):1449–1459
  303. Cuccuru G, Lanzi C, Cassinelli G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96(13):1006–1014
  304. Petrangolini G, Cuccuru G, Lanzi C, et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol. 2006;72(4):405–414
  305. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91(10):4070–4076
  306. Liu Z, Falola J, Zhu X, et al. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab. 2004;89(7):3503–3509
  307. Carlomagno F, Vitagliano D, Guida T, et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab. 2003;88(4):1897–1902
  308. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006;91(9):3662–3666
  309. Strock CJ, Park JI, Rosen M, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003;63(17):5559–5563
  310. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326–334
  311. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–7290
  312. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. 2005;65(9):3538–3541
  313. Wells SYY, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, et al. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol. 2006;24(18S):5533;(Meeting Abstracts)
  314. Boughton D, Rosen L, Van Vugt A, Kurzrock R, Eschenberg M, Wiezorek J, et al. Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): a subset analysis from a phase 1 dose-finding study. J Clin Oncol. 2006;24(18S):3030;(Meeting Abstracts)
  315. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005;11(3):1336–1341
  316. Strock CJ, Park JI, Rosen DM, et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab. 2006;91(1):79–84
  317. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003;349(16):1517–1525
  318. Parthasarathy R, Cote GJ, Gagel RF. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. 1999;59(16):3911–3914
  319. Drosten M, Frilling A, Stiewe T, Putzer BM. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery. 2002;132(6):991–997discussion 997
  320. Yano L, Shimura M, Taniguchi M, et al. Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther. 2000;11(7):995–1004
  321. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14(8):1169–1176
  322. Marsee DK, Venkateswaran A, Tao H, et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem. 2004;279(42):43990–43997
  323. Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 2005;3(4):e123
  324. Hennige AM, Lammers R, Hoppner W, et al. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology. 2001;142(10):4441–4447
  325. Zatelli MC, Piccin D, Tagliati F, et al. SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology. 2005;146(6):2692–2698
  326. Sanudo JR, Maranillo E, Leon X, et al. An anatomical study of anastomoses between the laryngeal nerves. Laryngoscope. 1999;109(6):983–987
  327. Sanders I, Wu BL, Mu L, et al. The innervation of the human larynx. Arch Otolaryngol Head Neck Surg. 1993;119(9):934–939
  328. Nasri S, Beizai P, Ye YM, et al. Cross-innervation of the thyroarytenoid muscle by a branch from the external division of the superior laryngeal nerve. Ann Otol Rhinol Laryngol. 1997;106(7 Pt 1):594–598
  329. Petro ML, Schweinfurth JM, Petro AB. Transcricothyroid, intraoperative monitoring of the vagus nerve. Arch Otolaryngol Head Neck Surg. 2006;132(6):624–628
  330. Marcus B, Edwards B, Yoo S, et al. Recurrent laryngeal nerve monitoring in thyroid and parathyroid surgery: the University of Michigan experience. Laryngoscope. 2003;113(2):356–361
  331. Udelsman R. Experience counts. Ann Surg. 2004;240(1):26–27
  332. Snyder SK, Hendricks JC. Intraoperative neurophysiology testing of the recurrent laryngeal nerve: plaudits and pitfalls. Surgery. 2005;138(6):1183–1191discussion 1191-2
  333. Witt RL. Recurrent laryngeal nerve electrophysiologic monitoring in thyroid surgery: the standard of care?. J Voice. 2005;19(3):497–500
  334. Yarbrough DE, Thompson GB, Kasperbauer JL, et al. Intraoperative electromyographic monitoring of the recurrent laryngeal nerve in reoperative thyroid and parathyroid surgery. Surgery. 2004;136(6):1107–1115
  335. Robertson ML, Steward DL, Gluckman JL, Welge J. Continuous laryngeal nerve integrity monitoring during thyroidectomy: does it reduce risk of injury?. Otolaryngol Head Neck Surg. 2004;131(5):596–600
  336. Hermann M, Hellebart C, Freissmuth M. Neuromonitoring in thyroid surgery: prospective evaluation of intraoperative electrophysiological responses for the prediction of recurrent laryngeal nerve injury. Ann Surg. 2004;240(1):9–17
  337. Beldi G, Kinsbergen T, Schlumpf R. Evaluation of intraoperative recurrent nerve monitoring in thyroid surgery. World J Surg. 2004;28(6):589–591
  338. Halsted . Auto and iso-transplantation in dogs of the parathyroid glandules. W. J Exp Med. 1908;11:175–198
  339. Lahey F. The transplantation of parathyroids in partial thyroidectomy. Surg Gynecol Obstet. 1926;508–509
  340. Wells SA, Christiansen C. The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery. 1974;75(1):49–55
  341. Hickey RC, Samaan NA. Human parathyroid autotransplantation: proved function by radioimmunoassay of plasma parathyroid hormone. Arch Surg. 1975;110(8):892–895
  342. Wingert DJ, Friesen SR, Iliopoulos JI, et al. Post-thyroidectomy hypocalcemia (Incidence and risk factors). Am J Surg. 1986;152(6):606–610
  343. Thompson NW, Harness JK. Complications of total thyroidectomy for carcinoma. Surg Gynecol Obstet. 1970;131(5):861–868
  344. Palazzo FF, Sywak MS, Sidhu SB, et al. Parathyroid autotransplantation during total thyroidectomy—does the number of glands transplanted affect outcome?. World J Surg. 2005;29(5):629–631
  345. Abboud B, Sargi Z, Akkam M, Sleilaty F. Risk factors for postthyroidectomy hypocalcemia. J Am Coll Surg. 2002;195(4):456–461
  346. Kikumori T, Imai T, Tanaka Y, et al. Parathyroid autotransplantation with total thyroidectomy for thyroid carcinoma: long-term follow-up of grafted parathyroid function. Surgery. 1999;125(5):504–508
  347. Tiong HY, White SA, Khanna DS, et al. An unusual presentation of follicular carcinoma of the thyroid. Thyroid. 2001;11(6):591–593
  348. Lo CY, Lam KY. Routine parathyroid autotransplantation during thyroidectomy. Surgery. 2001;129(3):318–323
  349. Huang J, Walker R, Groome PG, et al. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. Cancer. 2001;92(6):1411–1418
  350. Thomusch O, Machens A, Sekulla C, et al. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery. 2003;133(2):180–185
  351. Funahashi H, Satoh Y, Imai T, et al. Our technique of parathyroid autotransplantation in operation for papillary thyroid carcinoma. Surgery. 1993;114(1):92–96
  352. Ohman U, Granberg PO, Lindell B. Function of the parathyroid glands after total thyroidectomy. Surg Gynecol Obstet. 1978;146(5):773–778
  353. Shaha AR, Burnett C, Jaffe BM. Parathyroid autotransplantation during thyroid surgery. J Surg Oncol. 1991;46(1):21–24
  354. Cohen MS, Dilley WG, Wells SA, et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery. 2005;138(6):1033–1040discussion 1040-1
  355. Caccitolo JA, Farley DR, van Heerden JA, et al. The current role of parathyroid cryopreservation and autotransplantation in parathyroid surgery: an institutional experience. Surgery. 1997;122(6):1062–1067
  356. Brunt LM, Sicard GA. Current status of parathyroid autotransplantation. Semin Surg Oncol. 1990;6(2):115–121
  357. Feldman GL, Edmonds MW, Ainsworth PJ, et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG–>ATG) mutation. Surgery. 2000;128(1):93–98
  358. Wagner PK, Seesko HG, Rothmund M. Replantation of cryopreserved human parathyroid tissue. World J Surg. 1991;15(6):751–755
  359. Herrera MF, Grant CS, van Heerden JA, et al. The effect of cryopreservation on cell viability and hormone secretion in human parathyroid tissue. Surgery. 1992;112(6):1096–1101discussion 1101-2
  360. McHenry CR, Stenger DB, Calandro NK. The effect of cryopreservation on parathyroid cell viability and function. Am J Surg. 1997;174(5):481–484
  361. Walgenbach S, Rosniatowski R, Bittinger F, et al. Modified cryopreservation and xenotransplantation of human parathyroid tissue. Langenbecks Arch Surg. 1999;384(3):277–283
  362. Ulrich F, Steinmuller T, Rayes N, et al. Cryopreserved human parathyroid tissue: cell cultures for in vitro testing of function. Transplant Proc. 2001;33(1-2):666–667
  363. Bubenicek P, Kobylka P, Povysil C, et al. Viability of parathyroid gland tissue measured by flow cytometry. Cas Lek Cesk. 2003;142(10):620–624
  364. Lombardi CP, Raffaelli M, Princi P, et al. Video-assisted thyroidectomy: report on the experience of a single center in more than four hundred cases. World J Surg. 2006;30(5):794–800discussion 801
  365. Miccoli P, Berti P, Materazzi G, et al. Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg. 2004;199(2):243–248
  366. Asao T, Kuwano H, Yamaguchi S, et al. Videoscopic thyroidectomy with fine needle-type apparatuses: an approach that does not leave a scar on the neck or anterior chest. Surg Laparosc Endosc Percutan Tech. 2005;15(6):339–344
  367. Lombardi CP, Raffaelli M, Princi P, et al. Safety of video-assisted thyroidectomy versus conventional surgery. Head Neck. 2005;27(1):58–64
  368. Lombardi CPRM, Princi P, Lulli P, Rossi ED, Fadda G, Bellantone R. In: Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Vol. 6:Rome, Italy: Divisione di Endocrinochirurgia, Istituto di Clinica Chirurgica, Dipartimento di Scienze Chirurgiche, Universita Cattolica del Sacro Cuore; 2002;p. 1070–1073
  369. Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res. 2003;23(5A):3601–3606
  370. Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66(17):8715–8721

PII: S0011-3840(07)00196-7

doi: 10.1067/j.cpsurg.2007.12.010

Current Problems in Surgery
Volume 45, Issue 3 , Pages 156-250 , March 2008

Article Tools

* Image Usage & Resolution